23-29 January 2016
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Phenytoin trial results
A phase II trial has shown that phenytoin, an anti-epileptic drug, reduced damage to nerves caused optic neuritis. This is seen as an indicator that it could protect nerves from further damage by MS. The results were originally announced at a conference in April and now have been published by the Lancet.
MS Trust link: Phenytoin
Stem cell therapy review
An Australian review of research into HSCT (a type of stem cell therapy) suggests it could be an effective treatment. They describe it as "a sledgehammer approach for treating MS patients, [but] one that will be astoundingly effective when used on appropriately selected patients."
Source: MS News Today
MS Trust link: Stem cell therapy
Tysabri and risk of PML
A study of people taking Tysabri in France and Germany found that the rate of conversion to JCV positive status (developing antibodies to a virus that can cause PML) was higher than in the general population or people with MS who were not taking Tysabri. Researchers suggest more frequent monitoring
MS Trust link: Tysabri (natalizumab)